Metabolic syndrome in hypertensive patients was associated with a higher prevalence of left ventricular hypertrophy (57.7% vs 25.1%, P<0.00001), microalbuminuria, and hypertensive retinopathy.
Cross-Sectional (n=353)
Does the presence of metabolic syndrome amplify hypertension-related target organ damage in essential hypertensive patients without diabetes?
Metabolic syndrome significantly amplifies preclinical cardiac, renal, and retinal damage in essential hypertensive patients, independent of individual components.
Absolute Event Rate: 57.7% vs 25.1%
p-value: p=<0.00001
OBJECTIVES: The aim of our study was to analyse, in a wide group of essential hypertensive patients without diabetes mellitus, the influence of metabolic syndrome (MS) (defined according to the criteria laid down in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) on markers of preclinical cardiac, renal and retinal damage. DESIGN: Cross-sectional study. SETTING: Outpatient hypertension clinic. SUBJECTS AND METHODS: A total of 353 young and middle-aged hypertensives, free from cardiovascular and renal diseases (and 37% of whom had MS), underwent echocardiographic examination, microalbuminuria determination and non-mydriatic retinography. RESULTS: When compared with subjects without MS, hypertensive patients with MS exhibited more elevated left ventricular (LV) mass (either normalized by body surface area or by height elevated by a power of 2.7), higher myocardial relative wall thickness, albumin excretion rate (AER) and a greater prevalence of LV hypertrophy (57.7% vs. 25.1%; P < 0.00001), of microalbuminuria (36.2% vs. 19.3%; P = 0.002) and of hypertensive retinopathy (87.7% vs. 48.4%; P < 0.00001). These results held even after correction for age, 24-h blood pressures, duration of hypertension, previous antihypertensive therapy, and gender distribution. The independent relationships between LV mass and MS, and between AER and MS, were confirmed in multivariate regression models including MS together with its individual components. CONCLUSIONS: MS may amplify hypertension-related cardiac and renal changes, over and above the potential contribution of each single component of this syndrome. As these markers of target organ damage are well-known predictors of cardiovascular events, our results may partly explain the enhanced cardiovascular risk associated with MS.
Mulè et al. (Mon,) conducted a cross-sectional in Essential hypertension (n=353). Metabolic syndrome vs. Without metabolic syndrome was evaluated on Left ventricular hypertrophy (p=<0.00001). Metabolic syndrome in hypertensive patients was associated with a higher prevalence of left ventricular hypertrophy (57.7% vs 25.1%, P<0.00001), microalbuminuria, and hypertensive retinopathy.